Related Experiment Video
Updated: Sep 25, 2025
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
292
Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
Eric M Granowicz1, Brian A Jonas1
1Department of Internal Medicine, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Oncotargets and Therapy
|April 28, 2022
Summary
TP53-mutated acute myeloid leukemia (AML) is a rare but aggressive subtype with a poor prognosis. Emerging treatments show promise, but their effectiveness in TP53-mutated AML requires further investigation.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- TP53 is a crucial tumor suppressor gene involved in cellular stress responses.
- TP53 mutations define a high-risk subgroup of acute myeloid leukemia (AML) with dismal outcomes.
- Current treatments offer limited long-term survival for patients with TP53-mutated AML.
Purpose of the Study:
- To review the epidemiology, molecular features, and clinical impact of TP53 mutations in AML.
- To explore novel therapeutic strategies for TP53-mutated AML.
Main Methods:
- Literature review focusing on TP53 mutations in AML.
- Analysis of epidemiological data and molecular characteristics.
- Evaluation of current and emerging treatment options.
Main Results:
- TP53-mutated AML is associated with a significantly worse prognosis compared to other AML subtypes.
- Standard chemotherapy and stem cell transplantation yield poor survival rates.
- Novel agents show potential but require further clinical validation in this specific AML subgroup.
Conclusions:
- TP53-mutated AML represents a critical unmet need in hematologic malignancies.
- Understanding the molecular landscape is key to developing targeted therapies.
- Further research into novel treatment options is essential to improve patient outcomes.
